Corcept Therapeutics Incorporated (NASDAQ:CORT) was the target of a significant growth in short interest in the month of December. As of December 29th, there was short interest totalling 17,362,447 shares, a growth of 87.1% from the December 15th total of 9,280,017 shares. Based on an average trading volume of 3,744,451 shares, the days-to-cover ratio is currently 4.6 days. Currently, 17.3% of the company’s stock are sold short.

In other news, Director G Leonard Baker, Jr. sold 30,000 shares of the company’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $17.59, for a total transaction of $527,700.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Robert S. Fishman sold 8,000 shares of the company’s stock in a transaction on Monday, January 8th. The stock was sold at an average price of $18.67, for a total value of $149,360.00. Following the sale, the insider now directly owns 8,000 shares in the company, valued at approximately $149,360. The disclosure for this sale can be found here. Insiders have sold 46,000 shares of company stock worth $810,820 in the last ninety days. Corporate insiders own 19.20% of the company’s stock.

Hedge funds have recently modified their holdings of the business. California Public Employees Retirement System grew its holdings in shares of Corcept Therapeutics by 3.6% during the second quarter. California Public Employees Retirement System now owns 148,200 shares of the biotechnology company’s stock worth $1,749,000 after purchasing an additional 5,200 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of Corcept Therapeutics by 21.5% during the second quarter. Rhumbline Advisers now owns 87,672 shares of the biotechnology company’s stock worth $1,035,000 after purchasing an additional 15,494 shares during the last quarter. Prudential Financial Inc. grew its holdings in shares of Corcept Therapeutics by 3,409.5% during the second quarter. Prudential Financial Inc. now owns 633,223 shares of the biotechnology company’s stock worth $7,472,000 after purchasing an additional 615,180 shares during the last quarter. Shaker Investments LLC OH purchased a new position in shares of Corcept Therapeutics during the third quarter worth about $2,202,000. Finally, Sei Investments Co. grew its holdings in shares of Corcept Therapeutics by 344.8% during the third quarter. Sei Investments Co. now owns 17,562 shares of the biotechnology company’s stock worth $339,000 after purchasing an additional 13,614 shares during the last quarter. 64.64% of the stock is currently owned by institutional investors.

Several equities analysts recently commented on CORT shares. Piper Jaffray Companies set a $30.00 target price on Corcept Therapeutics and gave the company a “buy” rating in a report on Tuesday, October 31st. Zacks Investment Research lowered Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. Finally, BidaskClub lowered Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, December 20th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Corcept Therapeutics has a consensus rating of “Buy” and an average price target of $21.00.

Corcept Therapeutics (CORT) opened at $21.31 on Wednesday. The company has a market capitalization of $2,430.00, a price-to-earnings ratio of 73.48 and a beta of 1.89. Corcept Therapeutics has a twelve month low of $6.70 and a twelve month high of $21.75.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.13 by ($0.02). The firm had revenue of $42.70 million for the quarter, compared to analysts’ expectations of $41.64 million. Corcept Therapeutics had a return on equity of 58.17% and a net margin of 27.28%. The business’s revenue for the quarter was up 96.8% compared to the same quarter last year. During the same period in the previous year, the business posted $0.02 EPS. analysts anticipate that Corcept Therapeutics will post 0.47 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.dailypolitical.com/2018/01/16/corcept-therapeutics-incorporated-cort-sees-large-growth-in-short-interest.html.

About Corcept Therapeutics

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.